Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 26: 776-777, 1980;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chou, D.
Right arrow Articles by Eckfeldt, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chou, D.
Right arrow Articles by Eckfeldt, J. H.

Clinical Chemistry, Vol 26, 776-777, Copyright © 1980 by American Association for Clinical Chemistry

Interference by the 4-hydroxylated metabolite of propranolol with determination of metanephrines by the Pisano method

D Chou, M Tsuru, JL Holtzman and JH Eckfeldt

Measurements of urinary metanephrines by the Pisano procedure (Clin. Chim. Acta 5: 406, 1960) are unreliable in patients who are taking propranolol owing to the presence of 4-hydroxypropranolol in the urine. Three properties of this propranolol metabolite lead to interference: (a) it is absorbed and eluted from ion-exchange resins under the conditions Pisano used for metanephrine isolation, (b) at high pH it absorbs at 350 to 360 nm, and (c) it is oxidized by periodate to a substance with negligible absorption in this region. Because 350 to 360 nm is the wavelength used to quantitate vanillin, the product formed from periodate oxidation of metanephrines, and because the unoxidized eluate is used as a specimen blank, the presence of 4- hydroxypropranolol spuriously decreases the measured urinary metanephrines; this has special significance because patients being tested for increased metanephrines are also likely to be receiving propranolol for hypertension.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1980 by the American Association for Clinical Chemistry.